Searched for
PHARMA OUTSOURCING
Sai Life Sciences shares rally 9% after Q2 results; net profit rises 17%, revenue up 23%Sai Life Sciences shares jumped nearly 9% to a fresh 52-week high after strong second-quarter results. Revenue rose 23%, while net profit i...- Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watchIndia's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabil...
- AI productivity gains reflecting in salaries would take another 12 months: Wipro’s Jasjit KangWipro’s Jasjit Kang says broad productivity improvements remain elusive as the company looks for stronger AI, problem-solving and learning ...
- For long-term investors who know and accept that more trouble might be on the way: 5 mid-cap stocks with upside potential of up to 32%Headwinds continue to hit both the global and domestic markets. As the situation is unlikely to improve anytime soon, we may see a further ...
- Virtual pharma API firm HRV preparing for IPO, DRHP likely in H1 of 2027: SourcesHRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...
- Anthropic quietly sets up biology lab as it ramps AI drug programAt a time when fears of AI are gripping the public, the startup has built a wet lab, or place for physical experiments, in the San Francisc...
- MFs raise healthcare bets for 4th straight month to 71-month high. Should investors follow?Mutual funds raised their healthcare allocation for the fourth straight month in August 2026 to 8.4%, the highest in 71 months. Experts att...
- EV-related stocks: Own the chain, not the guess; 13 stocks with upside potential of up to 28% and downside risk of -14%, according to analystsIn the stock market, when a big theme or sectoral trend takes off, most investors focus on the face of it. A brand with which they can rela...
- Thinking long term and enduring volatility is the only way out: 5 mid-caps from different sectors with upside potential of up to 24%If you are an investor with some skin in the game, be ready to see some underperformance. Why? Because valuation readjustment can take more...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- NFO Insight: Invesco India Pharma and Healthcare Fund opens for subscription. Right time to invest in pharma funds?Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...
- NFO Alert: Invesco Mutual Fund announces launch of pharma and healthcare fundInvesco Mutual Fund has launched a new open-ended equity scheme. This fund will invest in India's evolving pharma and healthcare sectors. I...
- Obama's tax worries pharma tooApart from IT, the domestic pharma industry is also worried over President Obama's proposal to end tax breaks for US companies, which are e...
- Outsourcing from US to Indian pharma cos likely to be affectedWith Barack Obama's election as the President of the United States, outsourcing of activities from the US to the Indian pharma industry mig...
- 'Pharma outsourcing is a growing business'Ajay Piramal, chairman of Piramal Healthcare, spoke to ET about the company’s plans.
- Accenture to expand lifesciences R&D unitWith global pharma companies waking up to technology outsourcing services as a tool to reduce the time to market of their R&D harvest.
- PEs take fancy to pharma cos with outsourcing dealsSmall and mid-size pharma companies focused on outsourcing seem to have caught the attention of investors, if the recent investments by pri...
- Outsourcing radar picks up medical representativesINDIAN pharmaceutical companies are outsourcing a portion of their medical representative workforce, in a bid to become more competitive.
- Global pharma cos to outsource in IndiaClinical Research outsourcing (CRO) is a young industry worth about 118 million dollars a year in India, but it is growing fast.
- Now, BPOs moves towards researchAfter BPOs & KPOs, outsourcing segments are all set to move towards Research Process Outsourcing (RPO).
Load More
